ArticlePloS one2013

The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.

Jasjeet Bhullar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.